Market brief

European mRNA & Immunotherapy Supply Chain 2026

Europe holds a working mRNA and immunotherapy supply chain in 2026, but it is spread across specific sites rather than clustered in one country. Germany concentrates the mRNA innovation and manufacturing layer (BioNTech in Mainz, CureVac in Tübingen, AGC Biologics in Heidelberg as an mRNA CDMO, IDT Biologika in Dessau-Rosslau for viral-vector and fill-finish, BioSpring in Frankfurt for oligonucleotide GMP supply). Switzerland adds peptide and oligonucleotide API capacity through Bachem. The Nordic countries operate a separate vaccine and immunotherapy group - Bavarian Nordic for biodefence and MVA-BN, ALK-Abelló for allergen immunotherapy, Valneva Sweden for infectious-disease vaccines, and Statens Serum Institut as Denmark’s public-health reference. For sponsors planning an mRNA or immunotherapy programme, the practical question in 2026 is not "does Europe have the capacity" - it is which combination of the above sites fits a specific modality and timeline.

Summary

Key findings

BioNTech (Mainz) and CureVac (Tübingen) are the two German mRNA innovators in the directory. BioNTech ships at commercial scale; CureVac operates an RNA platform with translational and late-stage development activity disclosed publicly.
The European mRNA CDMO layer the directory surfaces includes AGC Biologics Heidelberg (published mRNA + pDNA + microbial services), IDT Biologika Dessau-Rosslau (viral vector and vaccine manufacturing), and BioSpring Frankfurt (oligonucleotide GMP supply).
Switzerland’s Bachem (Bubendorf) holds a large peptide and oligonucleotide API capacity, including peptide-oligo conjugates and synthetic oligonucleotides used upstream of mRNA, ASO, and peptide programmes.
The Nordic vaccine layer in the directory is distinct from the mRNA layer - Bavarian Nordic (Denmark) operates the MVA-BN platform, Valneva Sweden holds infectious-disease vaccine capacity, ALK-Abelló operates allergen immunotherapy manufacturing, and Statens Serum Institut runs Denmark’s public-health and reference labs.
First-pass shortlist

Separate an mRNA supply route from an mRNA innovator

Europe has mRNA innovators, specialist suppliers, and external manufacturing services, but they are not the same commercial route. Start with the material or service needed and confirm external availability, site scope, and programme fit directly with the named operator.

External mRNA or pDNA manufacturing

A CDMO route for mRNA, pDNA, or microbial intermediates

Heidelberg, Germany

Publicly stated scope
Start with AGC Biologics Heidelberg for its publicly described mRNA, pDNA, and microbial manufacturing services when the programme needs an external manufacturing conversation.
Confirm first
Starting material and modality, pDNA and mRNA scope, process-development needs, scale and GMP phase, analytical and release-testing model, drug-product handoff, technology transfer, and the named operating site.
Do not assume
That public mRNA or pDNA capability confirms a campaign slot, a particular scale, formulation route, or a complete end-to-end supply chain.
Oligonucleotide or peptide API

Synthetic upstream material supply

Frankfurt, Germany; Bubendorf, Switzerland

Publicly stated scope
Start with BioSpring or Bachem when the critical requirement is a publicly described synthetic oligonucleotide or peptide API route, then map the downstream drug-substance and drug-product steps separately.
Confirm first
Sequence and chemistry, GMP stage and scale, impurity profile, analytical package, conjugation or modification needs, regulatory market, and the formulation or fill-finish partner receiving the material.
Do not assume
That API manufacturing automatically provides mRNA drug substance, lipid formulation, fill-finish, or a complete vaccine manufacturing programme.
Viral-vector or vaccine drug product

A vector, vaccine, or specialised fill-finish route

Dessau-Rosslau, Germany; Nordic sites

Publicly stated scope
Start with IDT Biologika for its publicly described viral-vector and vaccine manufacturing scope; use the dedicated viral-vector or sterile fill-finish guide for a modality-specific shortlist.
Confirm first
Vector or vaccine type, biosafety and containment requirements, drug substance and fill-finish responsibilities, presentation, quality package, release testing, and the intended regulatory pathway.
Do not assume
That vaccine or viral-vector wording means the operator has an interchangeable service route for every product, presentation, or clinical stage.
mRNA platform or therapeutic collaboration

An innovator with an internal RNA platform or pipeline

Mainz and Tübingen, Germany

Publicly stated scope
Treat BioNTech and CureVac as potential innovation, research, or therapeutic-collaboration entities based on their public platforms and pipelines, not as presumed general-purpose external CDMOs.
Confirm first
Whether an external collaboration is open, the relevant therapeutic area and platform rights, evidence and development stage, manufacturing dependencies, territory, and the appropriate business-development route.
Do not assume
That commercial mRNA manufacturing or a public RNA platform is automatically offered as contract production, licensing, or co-development access.
Vaccine or immunotherapy partnership

A product, platform, or public-health route

Denmark and Sweden

Publicly stated scope
Start with Bavarian Nordic, ALK-Abelló, Valneva Sweden, or Statens Serum Institut only where the vaccine, allergen-immunotherapy, infectious-disease, or public-health context matches the stated activity.
Confirm first
Whether the need is commercial supply, a clinical collaboration, product access, research, or public-health coordination; also confirm indication, geography, rights, and the operating entity.
Do not assume
That a vaccine or immunotherapy manufacturer has a general external manufacturing service or an open partnership route for an unrelated programme.
Numbers

Quick numbers

German mRNA innovatorsBioNTech, CureVacMainz + Tübingen
mRNA CDMO capacityAGC Biologics, IDT BiologikaHeidelberg + Dessau-Rosslau
Oligo/peptide API anchorBachemBubendorf, Switzerland
Nordic vaccine anchorBavarian NordicKvistgaard, MVA-BN platform
Analysis

Germany as the mRNA innovation and manufacturing layer

The European mRNA layer concentrates in Germany. BioNTech in Mainz moved from pre-2020 platform developer to large-scale commercial mRNA manufacturing during the COVID era and now operates across infectious disease and oncology pipelines disclosed publicly. CureVac in Tübingen is the other German mRNA innovator in the directory - an RNA platform with translational and clinical development activity and a published oncology pipeline. Around these two innovators, Germany holds the mRNA CDMO and supply layer the directory surfaces: AGC Biologics Heidelberg publishes mRNA and pDNA manufacturing plus microbial bioprocessing, IDT Biologika Dessau-Rosslau runs viral-vector and vaccine fill-finish at commercial scale, and BioSpring in Frankfurt provides GMP oligonucleotide supply. For a sponsor planning an mRNA programme inside the EU, this is the geography the directory surfaces as most legible.

Analysis

Switzerland: peptide + oligonucleotide API capacity

Switzerland is not an mRNA manufacturer in the BioNTech sense, but it is where one of Europe’s larger synthetic oligonucleotide and peptide API operators sits. Bachem in Bubendorf holds peptide manufacturing at scale, including oligonucleotides and peptide-oligonucleotide conjugates. For programmes that combine synthetic oligo APIs with downstream biologics manufacturing elsewhere, Bachem is one of the European options on the API side. Around Bachem, Swiss pharma anchors (Novartis, Roche) and CDMOs (Lonza, Siegfried) absorb demand and build ADC / conjugate capacity that touches the same API supply.

Analysis

The Nordic vaccine and immunotherapy layer

The Nordic vaccine layer is separate from the German mRNA layer. Bavarian Nordic in Kvistgaard (Denmark) operates biodefence programmes and the MVA-BN vaccine platform, which has regulatory approval for smallpox and monkeypox use. Valneva Sweden in Stockholm holds infectious-disease vaccine capacity. ALK-Abelló in Horsholm operates allergen immunotherapy manufacturing. Statens Serum Institut in Copenhagen runs as Denmark’s public-health reference lab and national vaccine infrastructure. Alongside the broader Nordic immuno-oncology and vaccine-technology layer the directory surfaces (MinervaX, Abera Bioscience, ExpreS2ion, Nykode Therapeutics in Oslo), the Nordics read as a vaccine and immunotherapy group that complements, rather than substitutes, the German mRNA story.

Analysis

Supply chain and cross-border dynamics

mRNA and immunotherapy programmes move raw materials, APIs, and finished drug product across European borders more than most therapeutic modalities. Synthetic oligonucleotides from Frankfurt or Bubendorf move into formulation and fill-finish in Mainz, Heidelberg, or Dessau-Rosslau; viral-vector campaigns route through IDT Biologika; Nordic vaccine operators ship into the EU single market through GDP-certified logistics (DHL Life Sciences & Healthcare, World Courier, Kuehne+Nagel Healthcare). For sponsors planning a cross-border mRNA or immunotherapy footprint, the logistics layer is already a solved problem - the design work is about matching modality to the right German or Swiss operator, not about whether the supply chain can move the material.

Analysis

How to pick a European mRNA or immunotherapy partner in 2026

Three decisions drive partner selection. First, the modality: mRNA drug substance (BioNTech captive, CureVac captive, or AGC Biologics as CDMO); oligonucleotide API (Bachem or BioSpring); viral vector (IDT Biologika); MVA-BN (Bavarian Nordic captive); allergen immunotherapy (ALK-Abelló captive). Second, the scale: commercial-scale mRNA in Europe remains concentrated - for clinical-scale, more options open. Third, the geography and regulatory fit: EU-internal for simplicity; Switzerland for premium API with EU-aligned logistics. The Memel Biotech directory entry for each operator links to the current public disclosures so sponsors can verify capability before outreach.

What to watch

What to watch next

BioNTech Mainz capacity expansion and pipeline disclosures across infectious disease and oncology mRNA programmes
CureVac post-platform pipeline and manufacturing capacity announcements
AGC Biologics Heidelberg mRNA and pDNA capacity expansion
Bachem oligonucleotide capacity expansion announcements
Bavarian Nordic commercial capacity for MVA-BN and next-generation biodefence programmes
EU Biotech Act implementation effect on biomanufacturing scale-up funding
FAQ

Frequently asked questions

Who are the main European mRNA manufacturers in 2026?

BioNTech (Mainz) and CureVac (Tübingen) are the two German mRNA innovators the directory surfaces with in-house manufacturing. On the CDMO side, AGC Biologics Heidelberg publishes mRNA and pDNA manufacturing services, and IDT Biologika (Dessau-Rosslau) adds viral-vector and fill-finish capacity. For oligonucleotide API supply into mRNA and ASO programmes, BioSpring (Frankfurt) and Bachem (Bubendorf) are the two directory entries with that capability disclosed publicly.

Is Switzerland part of the European mRNA story?

Not as an mRNA drug-substance manufacturer, but yes on the API side. Bachem in Bubendorf holds peptide and oligonucleotide manufacturing at scale and supplies synthetic oligonucleotides into mRNA, ASO, and peptide-conjugate programmes. Lonza and Siegfried add adjacent biologics and CDMO capacity. For a sponsor combining synthetic APIs with EU manufacturing, Switzerland sits alongside Germany in the supply chain.

What role do the Nordics play in European vaccines?

The Nordic countries hold a separate vaccine and immunotherapy group. Bavarian Nordic (Denmark) operates the MVA-BN platform for smallpox, monkeypox, and biodefence use. Valneva Sweden (Stockholm) provides infectious-disease vaccine capacity. ALK-Abelló (Horsholm) runs allergen immunotherapy manufacturing. Statens Serum Institut (Copenhagen) operates as Denmark’s national vaccine and public-health reference infrastructure. Alongside Nordic immuno-oncology players the directory surfaces (MinervaX, Abera Bioscience, ExpreS2ion, Nykode Therapeutics) this layer complements the German mRNA story rather than substituting for it.

Can I run an mRNA programme entirely inside Europe in 2026?

Yes. mRNA drug substance at BioNTech, CureVac, or AGC Biologics; plasmid DNA and microbial intermediates at AGC Biologics; viral-vector adjuncts at IDT Biologika; oligonucleotide API through Bachem or BioSpring; fill-finish at Rentschler or Vetter; GDP-certified logistics through DHL / World Courier / Kuehne+Nagel. Every layer has a credible European operator. The design question is sequencing and capacity availability, not whether the supply chain exists.

How does Europe compare to the US for mRNA in 2026?

Europe is smaller than the US by commercial mRNA production volume but holds specific advantages: BioNTech as a commercial-scale mRNA operator, concentrated German innovation depth, EU-aligned regulatory pathways, and synthetic-API capacity in Bachem and BioSpring. For sponsors already working inside the EU regulatory system or targeting EU-market commercial launch, running the manufacturing footprint inside Europe removes a cross-regulatory layer and aligns with EMA-led clinical programmes.

Methodology note

Sources and interpretation

Sources: verified Memel Biotech directory entries for each operator, official company disclosures on mRNA, oligonucleotide, vaccine, and immunotherapy capabilities, and public regulatory filings. The directory entry for each operator links to the authoritative company sources.

Disclaimer

Use limits

This brief is an editorial map of visible European mRNA, vaccine, and immunotherapy capacity in 2026. It does not rank operators or disclose non-public capacity - sponsors should verify current capability, capacity availability, and regulatory status directly with each operator.

Primary sources

Source list

BioNTech corporate overviewCureVac RNA platformAGC Biologics Heidelberg capabilitiesBioSpring oligonucleotide manufacturingBavarian Nordic MVA-BN platform
Related pages

Related directory records

Verification methodologyLithuania biotech page (LT)
Briefs

Continue through related topics.

A useful brief should help people move into related records, cities, categories, and methodology pages without falling back into generic template language.

All briefsDirectory home